Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?

Jaroslaw J Fedorowski

doi:10.5114/aoms/134716

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?

Arch Med Sci. 2021 Mar 28;17(3):827-828. doi: 10.5114/aoms/134716. eCollection 2021.

Author

Jaroslaw J Fedorowski^{1

2

3

4}

Affiliations

¹ Polish Hospital Federation, Poland.
² Collegium Humanum Warsaw Management University, Warsaw, Poland.
³ College of Medicine and Health Network, University of Vermont, Vermont, United States.
⁴ Warsaw Maria Curie-Sklodowska Medical University, Warsaw, Poland.

Abstract

Introduction: Amantadine is a well-known medication with indications in neurology and infectious diseases. It is currently FDA approved for Parkinson's disease, drug-induced extrapyramidal symptoms, and influenza.

Methods: The article is the author's original research hypothesis.

Results: Because more people are going to be vaccinated and additional similar vaccines are going to be introduced, we should take into consideration the potential of amantadine to interfere with LNP-mRNA COVID-19 vaccine delivery into the target cells.

Conclusions: A more cautious approach to the patients taking amantadine as far as vaccination utilizing LNP-mRNA platform should be considered.

Keywords: COVID-19; LNP-mRNA; amantadine; vaccine.